Objective:: The correlations of serum interleukin-6 and soluble interleukin-6 receptor concentrations with clinicopathological features and survival of patients with colorectal cancer were studied. Methods: We measured the serum levels of interleukin-6 and soluble interleukin-6 receptor in 99 colorectal cancer patients at the Chang Gung Memorial Hospital, Taiwan. The interleukin-6 and soluble interleukin-6 receptor levels were tested for their association with each other, and with the clinical parameters and outcomes. Results: Both interleukin-6 and soluble interleukin-6 receptor concentrations were significantly higher in colorectal cancer patients than in normal individuals. Unlike patients with serum interleukin-6 levels .10 pg/ml, who have increased carcinoembryonic antigen levels and shorter survival, serum soluble interleukin-6 receptor levels .800 pg/ml were found in patients with stages I -II and no regional lymph nodal invasion and appeared to be a positive prognostic factor for improved survival. Especially, patients with serum interleukin-6 ,10 pg/ml and soluble interleukin-6 receptor .800 pg/ml lived significantly longer. Nonetheless, the multivariate analysis showed that only tumor-node metastasis stage, metastatic status and serum interleukin-6 level were independent prognostic factors, whereas the serum soluble interleukin-6 receptor level became marginally important for survival. Conclusions: We suggest the clinical relevance of interleukin-6 and soluble interleukin-6 receptor for the survival of colorectal cancer patients. From a practical point of view, detection of the serum interleukin-6 level alone, rather than combined measurement of interleukin-6 and soluble interleukin-6 receptor, may be sufficient to independently predict survival in colorectal cancer patients.
INTRODUCTION
Interleukin-6 (IL-6) is a pleiotropic cytokine that is produced by a wide variety of cells, mainly monocytes and macrophages, and it plays a central role in the regulation of the inflammatory and immune responses (1, 2) . IL-6 responses are mediated by specific membrane receptors on target cells (1) . IL-6 binds to a hexametric receptor, composed of a soluble IL-6 receptor alpha chain (sIL-6R, gp 80) and a signal transducer, gp 130, and the interaction of IL-6 and its receptor subsequently induces tyrosine phosphorylation (Tyr 705 ) of STAT3 proteins that bind directly to target genes (3 -5) .
It has been reported that by forming the IL-6/sIL-6R complex, sIL-6R promotes IL-6-mediated growth of a variety of cell types, including Kaposi's sarcoma cell line, hematopoietic progenitor cells and synovial fibroblasts (6 -8) . Hence, sIL-6R has the ability to expand the repertoire of cell types that are responsive to IL-6. In animal models, IL-6 transgenic mice exhibit elevated acute phase protein levels, and sIL-6R transgenic mice are hypersensitized to IL-6, mounting gene expression of acute phase gene protein at low IL-6 dosages, which persists longer (9) . The potential effect of sIL-6R on IL-6-mediated proliferation was further confirmed by IL-6/sIL-6R double transgenic mice, which developed nodules of hepatocellular hyperplasia and a myeloproliferative condition (10, 11) . Levels of sIL-6R are elevated in active inflammatory bowel diseases, rheumatoid arthritis and HIV infection (12 -14) . Taken together, sIL-6R appears to be a proinflammatory cytokine that performs an active role in regulating IL-6-mediated responses.
The preoperative IL-6 level is correlated with tumor stage, survival rate and liver metastasis in colorectal cancer (CRC) (15) (16) (17) (18) (19) . In vitro studies further demonstrated that IL-6 stimulates clonogenic growth of colon cancer cell lines and induces expression of surface antigens such as carcinoembryonic antigen (CEA) and human leukocyte antigen class I (HLA-I) (20, 21) . On the other hand, the expression of sIL-6R was reported to correlate with disease severity and cancer status (22 -24) . In multiple myeloma, the circulating extent of sIL-6R was associated with the stage and survival (22) ; high sIL-6R levels were found in patients with no treatment response and poor survival (23) . Changes in sIL-6R were detected in breast cancer patients at different stages of treatment; the serum sIL-6R levels in patients were lower than in normal individuals, but elevated after surgery (24) . Nonetheless, the clinical significance of sIL-6R in CRC has had little study. To the best of our knowledge, there has also been little investigation into the correlation between IL-6 and sIL-6R and the survival of CRC patients.
Therefore, the aim of the current study was to investigate the analysis of circulating IL-6 and sIL-6R levels on clinicopathological features and survival of patients with CRC. Our approach was to retrospectively measure the serum levels of IL-6 and sIL-6R in 99 CRC patients at the Chang Gung Memorial Hospital, Taiwan. The IL-6 and sIL-6 levels were tested for their association with each other, and with the clinical parameters and outcomes.
PATIENTS AND METHODS

STUDY PARTICIPANTS
The study population consisted of 99 patients undergoing resection of primary CRC at Chang Gung Memory Hospital between January 1995 and December 1995. No patient received chemotherapy or radiotherapy prior to surgery. Serum samples from patients were collected and stored at 2808C freezer before receiving surgical resection. The following parameters were recorded in all patients and analyzed in the study: age, gender, body mass index (BMI), co-morbidity status, history of tobacco and alcohol exposure, tumor location, tumor-node metastasis (TNM) stage, histological grading, hemoglobin level, white blood cell count, albumin level, hepatic and renal functions, and plasma CEA levels. The patients' ages ranged from 30 to 82 years (average age, 63.8 years). There were 56 males and 43 females. The tumor was located in the colon in 35 cases (35.3%) and in the rectum in 64 cases (64.7%). Tumors were re-classified retrospectively according to the 2002 American Joint Committee on Cancer Staging System (AJCC) based on physical examination, routine laboratory tests, chest X-ray and computerized tomography of the abdomen. Using these criteria, 19 patients had TNM stage I (19.2%), 33 patients had TNM stage II (33.3%), 30 patients had TNM stage III (30.3%) and 17 patients had TNM stage IV (17.2%). All patients had adenocarcinoma histology at the time of diagnosis. The histological grade was assessed by WHO criteria: 22 tumors were well differentiated (23.3%), 74 tumors were moderately differentiated (73.7%) and 3 tumors were poorly differentiated and undifferentiated (3.0%). The pathological diagnoses of all enrolled specimens were reviewed and confirmed by the CRC committee at Chang Gung Memory Hospital, Taiwan. The committee members included five colorectal surgeons, two medical oncologists, two radiation oncologists and two pathologists. The median follow-up duration was 7.8 years (range, 0.5 -11.5 years). Forty-two age-and gender-matched healthy blood donors with no previous cancer history served as controls. This study was approved by the Institutional Review Board, Chang Gung Memorial Hospital.
MEASUREMENTS OF SERUM IL-6 AND SIL-6R BY ENZYME-LINKED IMMUNOSORBENT ASSAY Blood was collected and centrifuged at 1,500 rpm for 15 minutes. The serum was collected and stored at 2808C in pyrogen-free plastic tubes until analysis. The serum IL-6 concentrations were determined using an enzyme-linked immunosorbent assay (ELISA) kit (R&D Systems, Minneapolis, MN, USA). The IL-6 concentrations were finally determined using a luminescence counter (Packard Instrument Company, USA). The serum sIL-6R concentrations were also measured using a DuoSet ELISA Development kit following the manufacturer's instructions (Catalog no.: DY227, R&D Systems). Using this assay, the values obtained corresponded to the total amount of sIL-6R Jpn J Clin Oncol 2010;40 (6) 581 present in the samples, i.e. the amount of the free receptors plus the amount of the receptors bound to IL-6. All samples were thawed only once and assayed in triplicate.
STATISTICAL ANALYSIS
Statistical analyses were performed using the SPSS statistical package, version 13.0 (SPSS, Inc., Chicago, IL, USA). The Pearson x 2 test was used to determine the associations among IL-6, sIL-6R and various clinicopathological features and survival rates of patients with CRCs. An independent Student's t-test was performed to analyze mean survival differences for IL-6 (.10 versus ,10 pg/ml) and sIL-6R (.800 versus ,800 pg/ml) subgroups. ANOVA was used to identify the mean survival difference among the four groups: IL-6 . 10 pg/ml and sIL-6R . 800 pg/ml (Group 1), IL-6 . 10 pg/ml and sIL-6R , 800 pg/ml (Group 2), IL-6 , 10 pg/ ml and sIL-6R . 800 pg/ml (Group 3), and IL-6 , 10 pg/ml and sIL-6R , 800 pg/ml (Group 4). The survival time data of each group were expressed as means + standard deviation. Overall survival was calculated from the date of diagnosis to the date of last follow-up or death from any cause and plotted using the Kaplan -Meier method. Multivariate analysis was performed using Cox's proportional hazards model. Patients who died of other causes were censored on the date of death. Patients lost to follow-up were included in all analyses and were censored on the date of last follow-up. All P values were derived from two-tailed statistical tests. A P value of ,0.05 was considered statistically significant.
RESULTS
In the entire group of patients, serum IL-6 concentrations ranged from 2.5 to 157.4 pg/ml, with a mean of 14.5 + 23.2 pg/ml and a median of 4.37 pg/ml; and sIL-6R concentrations ranged from 580.3 to 1323.6 pg/ml, with a mean of 836.8 + 152.2 pg/ml and a median of 808.6 pg/ml. These mean values were significantly higher in CRC patients than in healthy controls: IL-6 concentration, 3.53 + 9.37 pg/ml (P ¼ 0.011); and sIL-6R concentration, 695.2 + 132.3 pg/ml (P , 0.001). Patients' serum IL-6 levels did not correlate with serum sIL-6R concentrations (r ¼ 20.017, P ¼ 0.489). The actuarial survival rates for the 99 CRC patients were 67.7% at 3 years, 54.6% at 5 years and 40.4% at 10 years.
CORRELATION BETWEEN SERUM IL-6 LEVELS AND CLINICOPATHOLOGICAL VARIABLES
Serum IL-6 concentrations were not significantly associated with the following variables: gender, age, BMI at diagnosis, history of smoking and alcohol exposure, co-morbidity status, including hypertension, coronary artery disease, stroke events, diabetes mellitus, asthma and liver cirrhosis, TNM stage, tumor extent, regional lymph node invasion, distant metastatic involvement, and histological grade (Table 1) . Interestingly, the serum IL-6 level was significantly higher in patients with colonic disease than in those with rectal disease (P ¼ 0.045, Table 1 ).
Belluco et al. (16) reported that CRC patients with an IL-6 serum concentration of .10 pg/ml had a significantly shorter 5-year survival. Therefore, patients were stratified according to serum IL-6 concentration (.10 and ,10 pg/ ml). As shown in Table 2 , there was no significant association between serum IL-6 . 10/,10 pg/ml status and the following variables: gender, age, BMI at diagnosis, history of smoking and alcohol exposure, co-morbidity status, TNM stage, tumor extent, regional lymph node invasion, histological grade, hemoglobin level, white blood cell count, albumin level, and hepatic and renal functions (Table 2) . Interestingly, the IL-6 . 10 pg/ml group had a higher incidence of colonic disease and distant metastases than the IL-6 , 10 pg/ml group (Table 2 ). In accordance with the previous reports (16, 18) , the IL-6 . 10 pg/ml group expressed higher CEA concentrations than the IL-6 , 10 pg/ ml group (Table 2) .
CORRELATION BETWEEN SERUM SIL-6R LEVELS AND CLINICOPATHOLOGICAL VARIABLES
Serum sIL-6R concentrations were not significantly associated with the following variables: gender, age, history of smoking and alcohol exposure, co-morbidity status, tumor location, TNM stage, tumor extent, the presence of metastasis, and histological grade (Table 1) . On the other hand, the serum sIL-6R level was significantly higher in patients with a BMI ,25 kg/m 2 and no regional nodal involvement (Table 1) . Intriguingly, patients with stages I and II illness had higher serum sIL-6R concentrations than patients with stages III and IV (Table 1) .
Unlike IL-6, there has been no consensus regarding the optimal cut-off value of sIL-6R in CRC. Here, we arbitrarily used the median value of sIL-6R as the cut-off point in this study and further stratified patients according to serum sIL-6R concentration (.800 and ,800 pg/ml). As shown in Table 2 , there was no significant association between serum sIL-6R . 800/,800 pg/ml status and the following variables: gender, age, BMI at diagnosis, history of smoking and alcohol exposure, co-morbidity status, TNM stage, tumor extent, the presence of metastasis, histological grade, CEA concentration, hemoglobin level, white blood cell count, albumin level, and hepatic and renal functions. In contrast, the sIL-6R . 800 pg/ml group had a lower incidence of regional lymph nodal invasion, and fewer patients with stages III and IV illness, but higher incidence of well-differentiated histological grade than the sIL-6R , 800 pg/ml group (Table 2) .
RELATIONSHIPS BETWEEN SERUM IL-6 AND SIL-6R CONCENTRATIONS AND SURVIVAL As depicted in Table 2 , patients with IL-6 . 10 pg/ml had significantly shorter survival times and lower 3-, 5-and
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Serum IL-6 and sIL-6R levels in CRC 10-year survival rates than those with IL-6 , 10 pg/ml. On the other hand, the sIL-6R . 800 pg/ml group had significantly longer survival times and higher 3-and 5-year survival rates than the sIL-6R , 800 pg/ml group. There was no significant difference between the sIL-6R . 800 pg/ml group and the sIL-6R , 800 pg/ml group in 10-year survival (P ¼ 0.085).
To investigate the interactive effect of IL-6 and sIL-6R on survival, the patients were further stratified according to the status of serum IL-6 and sIL-6R concentrations into four groups, and their survivals were analyzed: IL-6 . 10 pg/ml and sIL-6R . 800 pg/ml (Group 1, 5.03 + 3.80 years, n ¼ 32), IL-6 . 10 pg/ml and sIL-6R , 800 pg/ml (Group 2, 4.11 + 4.34 years, n ¼ 37), IL-6 , 10 pg/ml and sIL-6R . 800 pg/ml (Group 3, 8.03 + 3.55 years, n ¼ 16), and IL-6 , 10 pg/ml and sIL-6R , 800 pg/ml (Group 4, 6.30 + 3.89 years, n ¼ 14). As depicted in Fig. 1 , patients in Group 3 had a significantly longer survival times than those in Groups 1 (P ¼ 0.044) and 2 (P ¼ 0.001). Nonetheless, no significant survival difference was detected in the following comparisons: Groups 1 and 2 (P ¼ 0.887), Groups 1 and 4 (P ¼ 0721), Groups 2 and 4 (P ¼ 0.207), and Groups 3 and 4 (P ¼ 0.267).
MULTIVARIATE SURVIVAL ANALYSIS
These data suggest that CRC patients with low serum IL-6 but high sIL-6R levels tend to live longer. To determine whether serum IL-6 and sIL-6R levels are independent prognostic factors for survival, multivariate analysis was performed using a Cox proportional hazards model (Table 3 ). In the 3-year survival analysis, early TNM stage, the absence of metastasis, BMI , 25 and IL-6 , 10 pg/ml were found to be significantly and independently associated with improved survival. In the 5-year analysis, the variables with a significant and independent impact on survival included early TNM stage, the absence of metastasis and IL-6 , 10 pg/ml. Furthermore, the status of no regional lymph node invasion became an independent prognostic factor for 10-year survival, in addition to early TNM stage, the absence of metastasis and IL-6 , 10 pg/ml. Serum sIL-6R concentration .800 pg/ml was found to be marginally significant as a prognostic factor for improved survival in the 3-year (P ¼ 0.065), 5-year (P ¼ 0.198) and 10-year (P ¼ 0.209) analyses.
DISCUSSION
Evidence has accumulated that high serum IL-6 levels are associated with circulating CEA and advanced stage (16) . In particular, a serum IL-6 level of .10 pg/ml is an independent, negative prognostic marker of survival (16) . Our observations demonstrated that the serum IL-6 level is higher in CRC patients than in controls and lend further support to the notion that there are significant associations between serum IL-6 concentration and metastasis status, circulating CEA levels, and survival in CRC patients. Jpn J Clin Oncol 2010;40(6) 583 
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Serum IL-6 and sIL-6R levels in CRC With the identification of its agonist property, sIL-6R is able to activate cell types that are inherently unresponsive to IL-6 alone (25). Increased sIL-6R levels have been described in various conditions, which implies that sIL-6R may regulate IL-6 responses and, consequently, disease progression (25) . Earlier studies into the association between sIL-6R and multiple myeloma and breast cancer suggested that high serum sIL-6R levels may be associated with poor prognosis (22 -24) . One in vitro report in CRC showed that neutrophilreleased sIL-6R enhanced adhesion of colon cancer cell line LS174T onto vascular endothelial cells and possibly affected the genesis of early metastasis (26) . Therefore, it is reasonable to imply that sIL-6R could potentially contribute to CRC progression. The current study demonstrated that serum sIL-6 levels were elevated in CRC patients compared with controls. In contrast, higher sIL-6R levels were found in patients with early TNM stage and without regional lymph node invasion. In addition, patients with sIL-6R levels .800 pg/ml had higher 3-and 5-year survival rates on univariate analysis. Furthermore, those who had both an IL-6 level ,10 pg/ml and an sIL-6R level .800 pg/ml had relatively longer survival (8.03 + 3.55 years). The data presented here suggest that unlike in multiple myeloma, sIL-6R appears to be a positive prognostic factor for improved survival in CRC. As far as we are aware, this is the first report to elucidate the relationship between serum sIL-6R levels and survival of CRC patients.
The cause of the difference in the prognostic role between multiple myeloma and CRC is presently unknown, but there are some in vitro and in vivo studies reporting that sIL-6R may be a functional antagonist to IL-6 by enhancing the inhibitory capacity of the soluble form of gp 130 (sgp 130) (27, 28) . The function of sgp 130 is to counteract the IL-6/ sIL-6R complex and, thereby, regulate the agonist role of sIL-6R. (29) . These reports found that the presence of sgp 130 was unable to block IL-6-induced activation of IL-6 receptor-positive cells, but inclusion of sIL-6R enhanced the antagonistic properties of sgp 130 by promoting formation of a tertiary complex (IL-6 -sIL-6R -sgp 130), thereby preventing IL-6 signaling through the cognate receptor.
Of the clinicopathological features and serum IL-6 and sIL-6R concentrations, only early TNM stage, the absence of distant metastasis and serum IL-6 ,10 pg/ml were independent prognostic factors for improved survival on multivariate analysis. Somewhat surprisingly, the effect of sIL-6R concentration on survival became marginally significant. Such an event might explain the inseparable association of IL-6 and sIL-6R in CRC. From a practical point of view, we suggest that detection of the serum IL-6 level alone, rather than combined measurement of IL-6 and sIL-6R, may be sufficient to independently predict survival in CRC patients.
One possible criticism of the current study could be the serum sIL-6R levels, which were far lower than in multiple myeloma and breast cancer patients. One study reported that Figure 1 . Kaplan -Meier survival analysis for the 99 colorectal cancer patients according to the status of serum interleukin-6 (IL-6) and soluble interleukin-6 receptor (sIL-6R) concentrations: IL-6 . 10 pg/ml and sIL-6R . 800 pg/ml (Group 1, triangles), IL-6 . 10 pg/ml and sIL-6R , 800 pg/ml (Group 2, diamonds), IL-6 , 10 pg/ml and sIL-6R . 800 pg/ml (Group 3, circles), and IL-6 , 10 pg/ml and sIL-6R , 800 pg/ml (Group 4, squares). Jpn J Clin Oncol 2010;40(6) 585 the sIL-6R amount released from neutrophils stimulated by lipopolysaccharide ranged from 100 to 200 pg/ml (26) . So far, there is no consensus regarding the distribution of sIL-6R among CRC patients. This discrepancy might, in part, be explained by cancer cell types and the sensitivity of the ELISA detection kit used.
In conclusion, our findings demonstrated that serum concentrations of both IL-6 and sIL-6R were significantly higher in CRC patients than in normal individuals. Patients with high serum IL-6 concentrations had increased CEA levels and shorter survival. In contrast, a high serum IL-6R level was found in patients with a BMI , 25, stages I -II and no regional nodal invasion, and it appeared to be a positive prognostic factor for improved survival. Simultaneous measurement of IL-6 and sIL-6R levels showed that CRC patients with low IL-6 but high sIL-6R concentrations had longer survival. The multivariate analysis identified only three significant prognostic factors for survival: TNM stage, metastatic status and serum IL-6 level. The serum sIL-6R level, however, became marginally important for survival. This new information suggests the clinical relevance of serum IL-6 and sIL-6R levels for survival of CRC patients. The biological significance of the interaction between IL-6 and sIL-6R in CRC patients deserves further investigation.
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